UPDATE: Eurogamer has just received the official press release on Warface.
Warface, co-developed by Crytek Seoul, is a free-to-play PC-exclusive military shooter set in the near future. It offers a "cinematic experience with next gen visuals, AI and physics".
It is indeed based on CryENGINE 3. There's a "constantly updated extensive" player versus environment universe, with multiplayer and co-op missions. There's a full set of class-based player versus player, too.
Warface is a PC exclusive "especially dedicated to the Korean and other Asian markets".
"Our passion is to always deliver the best gaming experience possible. That's why we opened our Crytek Korea office in 2008, which today enables us to offer a game that is tailored to suit its market. We're excited to debut with Warface in South Korea and to deliver a compelling and truly unique experience soon." said Cevat Yerli, CEO & President of Crytek.
ORIGINAL STORY: Crysis creator Crytek's Korean studio has unveiled a new game, a shooter called Warface.
The website's in Chinese – here's a very rough translation: "Crytek today opens its new generation of online first-person shooting game "WARFACE", first revealed the game screen with some content." Yes, we know.
It sounds like Warface has an online focus, and is being built using Crytek's own CryEngine 3. "I hope to convey to the players a new and exciting fighting experience," said Crytek CEO Cevat Yerli. Platforms and launch window were not mentioned.
Crytek opened an office in South Korea on 17th November 2008, with a focus on licensing CryEngine to clients.
That's your lot for now. We're digging...
Will you support Eurogamer?
We want to make Eurogamer better, and that means better for our readers - not for algorithms. You can help! Become a supporter of Eurogamer and you can view the site completely ad-free, as well as gaining exclusive access to articles, podcasts and conversations that will bring you closer to the team, the stories, and the games we all love. Subscriptions start at £3.99 / $4.99 per month.